

YEAR-END REPORT – Extract from the official Swedish report

1 January – 31 December 2016
(NGM: LIFE B)



Financial information

Group

- Net sales for the period January – December 2016 totals 7 456 (4 785) kSEK
- Profit after taxes totals – 19 027 (-17 492) kSEK.
- Profit per share was – 0,016 (-0,06) kr.

Parent company

- Net sales for the period January – December 2016 totaled 7 456 (4 755) kSEK.
- Profit after taxes totals – 16 517 (-15 674) kSEK.
- Profit per share was – 0,014 (-0,06) SEK.



LifeAssays® AB's business idea is to develop, manufacture and sell diagnostic systems based on the company's own and patented technology MagnetoImmunoAssay (MLA). The company delivers safe and robust systems for quick and reliable analysis in veterinary medicine. The company's patented products consist of instruments and disposable reagent which is harmless to patients, staff and the environment. Alternative markets for the company's products are in human medicine as well as food and pharmaceutical industries.

CEO comments

Fourth quarter 2016

- Net sales for the Group as well as for the parent during the quarter was 1 833 kSEK which is an increase by 48% over the fourth quarter in 2015.
- Increase in number of tests sold by 37% over the fourth quarter 2015.
- The company has strengthened its network of distributors in UK, Germany, Italy, Lithuania and Thailand.
- The cancer study is continuing with a slight delay. Phase One will be summarized during February 2017 and Phase Two will commence as soon as the summary for Phase One is completed.
- Agreement with Vettris, a hard investing group of veterinary clinics, was closed during the fourth quarter.
- Pre-launch of LifeAssays new test for cat-SAA has generated lots of attention.
- The project with the quantitative disposable test is progressing in accordance with plan and resources will be added in order to assure the completion of a prototype during the fourth quarter.

15th of February 2016

Anders Ingvarsson, MSc

VD för LifeAssays AB

anders.ingvarsson@lifeassays.com

Share information & owner structure

The share price (last transaction) for the quarter was 0,049 (0,059) SEK, which gives a market cap of 81,2 (23,8) mSEK. The nominal value is 0,02 kr.

The average number of shares for the period was 1 199 765 939 shares.

Largest owners 31st of December 2016	No of shares	Votes/capital
Tibia Konsult AB	148 194 934	8,95%
Biothom Oy	108 608 931	6,56%
Avanza Pension	93 931 425	5,67%
Matz Eklund	49 793 872	3,01%
Peter Schlein-Andersen	47 850 000	2,89%
Bo Göran Åkerlund	40 000 000	2,41%
Svenska Handelsbanken Markets	38 608 722	2,33%
Nordnet Pensionsförsäkring AB	37 173 567	2,24%
Christian Borgvall	19 000 000	1,15%
AN Holding	18 000 000	1,09%
Others (4 951 st)	1 055 181 783	63,71%
Total	1 656 343 234	100,00%

Outstanding warrants

There are currently 482 970 502 warrants outstanding. Each warrant entitles to subscription of one share at 70% of the volume weighted average price during the 20 days succeeding the release of the Q4 report for 2016. In the event of the Company not having released the Q4 report the calculation period shall start on the 27th of February 2017. The minimum price is set at the nominal value, 0,02 SEK and the maximum price is set at 0,06 SEK. A full redemption of the warrants will increase the share capital by 9 659 kSEK.

Financial calendar

Q4 report 2016	Wednesday 15 th February 2017
Annual report 2016	6 th April 2017
Q1 report 2017	27 th April 2017

Contact information:

LifeAssays® AB, Scheelevägen 19F:2, 223 70 LUND, tel +46 46-286 5400, fax +46 46-286 5419
Web: www.lifeassays.com, epost: info@lifeassays.com

For further information contact CEO of LifeAssays AB, Anders Ingvarsson, telephone +46 46-286 54 00 or email: info@lifeassays.com

Condensed statement of comprehensive income - Gruop

TSEK	2016	2015	2016	2015
	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Net sales				
Net sales	1 833	1 241	7 456	4 755
Other income	31	0	111	30
Total net sales	1 864	1 241	7 567	4 785
Operating expenses				
Raw materials and consumables	-750	-719	-3 231	-2 624
Other external expenses	-2 291	-1 791	-9 131	-8 664
Personnel expenses	-3 439	-2 884	-12 367	-10 225
Depreciation and writedowns of intangible and tangible assets	-393	-177	-1 482	-656
Other operating income/cost	-27	-20	-104	-83
Total operating expenses	-6 900	-5 591	-26 315	-22 252
Operating profit/loss	-5 036	-4 350	-18 748	-17 467
Profit /loss from financial activities				
Interest income	0	4	54	15
Interest expenses	-125	-14	-351	-30
Profit before taxes	-5 161	-4 360	-19 045	-17 482
Taxes	0	0	18	-10
Profit/loss for the period	-5 161	-4 360	-19 027	-17 492
TSEK	2016	2015	2016	2015
	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Profit/loss for the period	-5 161	-4 360	-19 027	-17 492
Items that may be reclassified to the income statement:				
Translation differences	-10	-	147	-62
Total comprehensive income for the period	-5 171	-4 360	-18 880	-17 554
Key ratios:				
Earnings per share before and after dilution	-0,003	-0,010	-0,016	-0,06
Average number of shares	1 656 343 234	402 658 286	1 199 765 939	284 617 096
Number of shares at the end of the period	1 656 343 234	402 658 286	1 656 343 234	402 658 286

Condensed consolidated balance sheet - Group

TSEK	2016-12-31	2015-12-31
Assets		
Fixed assets		
Intangible fixed assets	19 266	17 334
Tangible assets	459	240
Financial fixed assets		
Total fixed assets	19 725	17 574
Current assets		
Inventories	1 830	2 124
Other current assets	2 889	2 269
Liquid assets, including current investments	8 472	5 659
Total current assets	13 191	10 052
Total assets	32 916	27 626
Liabilities and shareholders equity		
Share capital	33 127	20 133
Other capital contributed	141 262	131 911
Reserves	85	-62
Profit/Loss brought forward	-137 846	-120 355
Total comprehensive income for the period	-19 027	-17 492
Total equity	17 601	14 135
Long term liabilities		
	9 763	8 566
Deferred tax liabilities	2 022	1 948
Total long-term liabilities	11 785	10 514
Current liabilities		
Other current liabilities	3 530	2 977
Total current liabilities	3 530	2 977
Total liabilities and shareholders equity	32 916	27 626

Consolidated Cash flow statement - Group

TSEK	2016	2015	2016	2015
	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Operating activities				
Operating profit/loss	-5 036	-4 350	-18 748	-17 467
Interest received	0	17	54	15
Interest paid	-126	-1	-351	-30
Other items not included in cash flow	490	177	1 759	679
Cash flow from operating activities before changes in working capital	-4 672	-4 157	-17 286	-16 803
Change in operating receivables	156	-43	294	-334
Change in inventory	407	-121	-592	-132
Change in operating liabilities	369	214	492	329
Cash flow from operating activities	-3 740	-4 107	-17 092	-16 940
Investment activities				
Intangible assets	-940	-129	-2 702	-616
Fixed assets	-9	-23	-322	-52
Investment in net assets in group companies	-	-1 506	-	46
Total cash flow from investment activities	-949	-1 658	-3 024	-622
Financing activities				
New share issue	-	-	22 345	14 026
Change in financial receivables	-161	21	570	-
Cash flow from financing activities	-161	21	22 915	14 026
Cash flow for the period	-4 850	-5 744	2 799	-3 536
Liquid assets at the beginning of the period	13 331	11 403	5 659	9 200
Exchange rate difference liquid assets	-9	-	14	-5
Cash flow for the period	-4 850	-5 744	2 799	-3 536
Liquid assets at the end of the period	8 472	5 659	8 472	5 659
Key ratios - Group	2 016	2015	2 016	2015
	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Equity/asset ratio (%)	53%	89%	53%	51%
Return on equity	neg	neg	neg	neg
Profit/loss after finance net (TSEK)	-5 161	-4 360	-19 045	-17 482
Profit/loss per share (sek/share)	-0,003	-0,010	-0,016	-0,060
Cash flow (TSEK)	-4 850	-5 744	2 799	-3 536

Consolidated changes in shareholders equity

TSEK	Share capital	Other capital contributed	Reserves	Profit/loss brought forward	Profit/loss for the year	Shareholders equity
Opening balance	20 133	131 911	-62	-120 354	-17 492	14 136
Disposition of previous years' result				-17 492	17 492	0
Ongoing share issue	4 016	-4 016				0
Reduction of share capital	-14 489	14 489				0
Share issue	19 319	-1023				18 296
Redemption of warrants	4 148	-99				4 049
Translation difference group companies			147			147
Profit/loss for the year					-19 027	-19 027
Closing balance	33 127	141 262	85	-137 846	-19 027	17 601

Segment information

Split of Net sales per product group	2016	2015	2016	2015
	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Tester	1471	869	6342	3760
Instrument	175	66	868	618
Övrigt	187	306	245	377
Total	1 645	1 241	7 455	4 755

Net sales per region (Split based on where the customers are established)	2016	2015	2016	2015
	Oct-Dec	Oct-Dec	Jan-Dec	Jan-Dec
Nordic	1 150	927	4 879	2 795
Europé	178	28	453	286
North America	0	8	19	214
Asia	505	278	2 104	1 490
Total	1 833	1 241	7 455	4 785